[CIMB] QoQ Annualized Quarter Result on 31-Mar-2017 [#1]

Announcement Date
24-May-2017
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2017
Quarter
31-Mar-2017 [#1]
Profit Trend
QoQ- 32.46%
YoY- 45.03%
View:
Show?
Annualized Quarter Result
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
Revenue 17,626,496 17,481,334 17,375,714 17,441,988 16,065,255 15,669,508 15,256,778 10.07%
PBT 6,109,985 6,099,474 6,094,510 6,454,392 4,884,144 4,896,653 4,623,480 20.36%
Tax -1,502,019 -1,413,374 -1,395,998 -1,610,388 -1,251,187 -1,223,938 -1,212,066 15.32%
NP 4,607,966 4,686,100 4,698,512 4,844,004 3,632,957 3,672,714 3,411,414 22.12%
-
NP to SH 4,475,175 4,553,261 4,565,444 4,721,032 3,564,190 3,613,073 3,373,260 20.67%
-
Tax Rate 24.58% 23.17% 22.91% 24.95% 25.62% 25.00% 26.22% -
Total Cost 13,018,530 12,795,234 12,677,202 12,597,984 12,432,298 11,996,793 11,845,364 6.47%
-
Net Worth 47,841,687 47,623,511 46,850,748 46,749,209 45,091,606 43,398,371 41,741,725 9.49%
Dividend
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
Div 2,287,062 1,555,238 2,338,849 - 1,765,183 921,996 1,376,138 40.17%
Div Payout % 51.11% 34.16% 51.23% - 49.53% 25.52% 40.80% -
Equity
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
Net Worth 47,841,687 47,623,511 46,850,748 46,749,209 45,091,606 43,398,371 41,741,725 9.49%
NOSH 9,225,547 8,972,532 9,052,110 8,867,452 8,868,384 8,643,716 8,600,866 4.77%
Ratio Analysis
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
NP Margin 26.14% 26.81% 27.04% 27.77% 22.61% 23.44% 22.36% -
ROE 9.35% 9.56% 9.74% 10.10% 7.90% 8.33% 8.08% -
Per Share
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
RPS 192.68 194.83 193.16 196.70 182.02 181.28 177.39 5.65%
EPS 49.63 50.75 51.12 53.24 41.00 41.80 39.22 16.94%
DPS 25.00 17.33 26.00 0.00 20.00 10.67 16.00 34.54%
NAPS 5.2296 5.3077 5.2082 5.272 5.109 5.0208 4.8532 5.09%
Adjusted Per Share Value based on latest NOSH - 8,867,452
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
RPS 164.43 163.08 162.10 162.71 149.87 146.18 142.33 10.07%
EPS 41.75 42.48 42.59 44.04 33.25 33.71 31.47 20.67%
DPS 21.34 14.51 21.82 0.00 16.47 8.60 12.84 40.17%
NAPS 4.4631 4.4427 4.3706 4.3612 4.2065 4.0486 3.894 9.49%
Price Multiplier on Financial Quarter End Date
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
Date 29/12/17 29/09/17 30/06/17 31/03/17 30/12/16 30/09/16 30/06/16 -
Price 6.54 6.30 6.58 5.57 4.51 4.71 4.37 -
P/RPS 3.39 3.23 3.41 2.83 2.48 2.60 2.46 23.76%
P/EPS 13.37 12.41 12.96 10.46 11.17 11.27 11.14 12.89%
EY 7.48 8.06 7.71 9.56 8.95 8.87 8.97 -11.37%
DY 3.82 2.75 3.95 0.00 4.43 2.26 3.66 2.88%
P/NAPS 1.25 1.19 1.26 1.06 0.88 0.94 0.90 24.40%
Price Multiplier on Announcement Date
31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 CAGR
Date 28/02/18 28/11/17 28/08/17 24/05/17 28/02/17 16/11/16 29/08/16 -
Price 7.19 5.96 6.78 5.98 4.97 4.79 4.80 -
P/RPS 3.73 3.06 3.51 3.04 2.73 2.64 2.71 23.66%
P/EPS 14.70 11.74 13.36 11.23 12.31 11.46 12.24 12.94%
EY 6.80 8.51 7.49 8.90 8.13 8.73 8.17 -11.48%
DY 3.48 2.91 3.83 0.00 4.02 2.23 3.33 2.97%
P/NAPS 1.37 1.12 1.30 1.13 0.97 0.95 0.99 24.10%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment